China Oncology ›› 2022, Vol. 32 ›› Issue (10): 979-989.doi: 10.19401/j.cnki.1007-3639.2022.10.006
• Article • Previous Articles Next Articles
ZHU Yi1,3(), XIAO Bin1, LIU Jiahui2, HUANG Ling2, SUN Zhaohui2, LI Linhai1
Received:
2022-03-24
Revised:
2022-08-04
Online:
2022-10-30
Published:
2022-11-29
CLC Number:
ZHU Yi, XIAO Bin, LIU Jiahui, HUANG Ling, SUN Zhaohui, LI Linhai. Expression, localization, biological role and proteomics study of circ-0003910 in HER2-positive breast cancer[J]. China Oncology, 2022, 32(10): 979-989.
Fig. 2
Circ-0003910 was up-regulated in HER2 positive breast cancer cells A-C: Heat map of differentially expressed circRNA; D-F: Scatter plots of differentially expressed circRNA; G: Heat map of the top 20 circRNA with the highest differential expression; H: Expression of circ-0003910 in five types of breast cancer cells and normal breast cells; I: Subcellular localization of circ-0003910 in SK-BR-3 cells; *: P<0.05, **: P<0.01, ***: P<0.001, compared with MCF-10A."
Fig. 4
Circ-0003910 promotes breast cancer cell migration and invasion in vitro A-B: The mRNA expression level of CIRC-0003910 was detected after overexpression and knockdown of circ-0003910 by RTFQ-PCR; C: Transwell assay detected the migration and invasion of MDA-MB-231 cells when circ-0003910 was overexpressed; D: Transwell assay detects the migration and invasion of SK-BR-3 cells when circ-0003910 was knocked down. **: P<0.01, compared with each other; ***: P<0.001, compared with each other."
Fig. 5
GO enrichment analysis of downstream differentially expressed proteins affected by circ-0003910 overexpression A: GO analysis of differentially expressed proteins enriched in biological process; B: GO analysis of differentially expressed proteins enriched in cellular component; C: GO analysis of differentially expressed proteins enriched in molecular function"
[1] |
SUNG H, FERLAY J, SIEGEL R L, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2021, 71(3): 209-249.
doi: 10.3322/caac.21660 |
[2] |
YEO S K, GUAN J L. Breast cancer: multiple subtypes within a tumor?[J]. Trends Cancer, 2017, 3(11): 753-760.
doi: S2405-8033(17)30175-9 pmid: 29120751 |
[3] |
HARBECK N, GNANT M. Breast cancer[J]. Lancet, 2017, 389(10074): 1134-1150.
doi: S0140-6736(16)31891-8 pmid: 27865536 |
[4] | 王笑. HER2阳性乳腺癌中KIF3B表达意义及其与上皮间质转化的相关性研究[D]. 青岛: 青岛大学, 2021. |
WANG X. Significance of KIF3B expression in HER2 positive breast cancer and its correlation with epithelial mesenchymal transition[D] Qingdao: Qingdao University, 2021. | |
[5] |
ZHENG Q P, BAO C Y, GUO W J, et al. Circular RNA profiling reveals an abundant circHIPK3 that regulates cell growth by sponging multiple miRNAs[J]. Nat Commun, 2016, 7: 11215.
doi: 10.1038/ncomms11215 pmid: 27050392 |
[6] |
YIN Y T, LONG J L, HE Q L, et al. Emerging roles of circRNA in formation and progression of cancer[J]. J Cancer, 2019, 10(21): 5015-5021.
doi: 10.7150/jca.30828 pmid: 31602252 |
[7] |
LIN X S, HUANG C, CHEN Z A, et al. CircRNA_100876 is upregulated in gastric cancer (GC) and promotes the GC cells' growth, migration and invasion via miR-665/YAP1 signaling[J]. Front Genet, 2020, 11: 546275.
doi: 10.3389/fgene.2020.546275 |
[8] |
LIU H L, LAN T, LI H, et al. Circular RNA circDLC1 inhibits MMP1-mediated liver cancer progression via interaction with HuR[J]. Theranostics, 2021, 11(3): 1396-1411.
doi: 10.7150/thno.53227 pmid: 33391541 |
[9] |
CHEN D S, MA W, KE Z Y, et al. CircRNA hsa_circ_100395 regulates miR-1228/TCF21 pathway to inhibit lung cancer progression[J]. Cell Cycle, 2018, 17(16): 2080-2090.
doi: 10.1080/15384101.2018.1515553 pmid: 30176158 |
[10] |
LIU Z H, ZHOU Y, LIANG G H, et al. Circular RNA hsa_circ_001783 regulates breast cancer progression via sponging miR-200c-3p[J]. Cell Death Dis, 2019, 10(2): 55.
doi: 10.1038/s41419-018-1287-1 pmid: 30670688 |
[11] | 王晓松, 陈俊霞. 环状RNA hsa_circ_0050900在乳腺癌中的表达及其对细胞生物学行为影响的机制研究[J]. 中国癌症杂志, 2020, 30(12): 977-983. |
WANG X S, CHEN J X. Expression of circular RNA has_circ_0050900 in breast cancer and its effect on cell function[J]. China Oncol, 2020, 30(12): 977-983. | |
[12] |
LUO Z, RONG Z Y, ZHANG J M, et al. Circular RNA circCCDC9 acts as a miR-6792-3p sponge to suppress the progression of gastric cancer through regulating CAV1 expression[J]. Mol Cancer, 2020, 19(1): 86.
doi: 10.1186/s12943-020-01203-8 pmid: 32386516 |
[13] |
XU J Z, SHAO C C, WANG X J, et al. circTADA2As suppress breast cancer progression and metastasis via targeting miR-203a-3p/SOCS3 axis[J]. Cell Death Dis, 2019, 10(3): 175.
doi: 10.1038/s41419-019-1382-y |
[14] | ZEESHAN R, MUTAHIR Z. Cancer metastasis-tricks of the trade[J]. Bosn J Basic Med Sci, 2017, 17(3): 172-182. |
[15] |
LI T, MELLO-THOMS C, BRENNAN P C. Descriptive epidemiology of breast cancer in China: incidence, mortality, survival and prevalence[J]. Breast Cancer Res Treat, 2016, 159(3): 395-406.
doi: 10.1007/s10549-016-3947-0 |
[16] |
ZANG J K, LU D, XU A D. The interaction of circRNAs and RNA binding proteins: an important part of circRNA maintenance and function[J]. J Neurosci Res, 2020, 98(1): 87-97.
doi: 10.1002/jnr.24356 pmid: 30575990 |
[17] |
KRISTENSEN L S, ANDERSEN M S, STAGSTED L V W, et al. The biogenesis, biology and characterization of circular RNAs[J]. Nat Rev Genet, 2019, 20(11): 675-691.
doi: 10.1038/s41576-019-0158-7 pmid: 31395983 |
[18] | KLINGE C M. Non-coding RNAs in breast cancer: Intracellular and intercellular communication[J]. Noncoding RNA, 2018, 4(4): 40. |
[19] |
KIRBY E, TSE W H, PATEL D, et al. First steps in the development of a liquid biopsy in situ hybridization protocol to determine circular RNA biomarkers in rat biofluids[J]. Pediatr Surg Int, 2019, 35(12): 1329-1338.
doi: 10.1007/s00383-019-04558-2 |
[20] |
HUANG A Q, ZHENG H X, WU Z Y, et al. Circular RNA-protein interactions: functions, mechanisms, and identification[J]. Theranostics, 2020, 10(8): 3503-3517.
doi: 10.7150/thno.42174 pmid: 32206104 |
[21] |
HU C J, NI Z H, LI B S, et al. hTERT promotes the invasion of gastric cancer cells by enhancing FOXO3a ubiquitination and subsequent ITGB1 upregulation[J]. Gut, 2017, 66(1): 31-42.
doi: 10.1136/gutjnl-2015-309322 pmid: 26370108 |
[22] |
REN L L, MO W J, WANG L L, et al. Matrine suppresses breast cancer metastasis by targeting ITGB1 and inhibiting epithelial-to-mesenchymal transition[J]. Exp Ther Med, 2020, 19(1): 367-374.
doi: 10.3892/etm.2019.8207 pmid: 31853313 |
[23] |
TAFTAF R, LIU X, SINGH S, et al. ICAM1 initiates CTC cluster formation and trans-endothelial migration in lung metastasis of breast cancer[J]. Nat Commun, 2021, 12(1): 4867.
doi: 10.1038/s41467-021-25189-z pmid: 34381029 |
[24] |
FIGENSCHAU S L, KNUTSEN E, URBAROVA I, et al. ICAM1 expression is induced by proinflammatory cytokines and associated with TLS formation in aggressive breast cancer subtypes[J]. Sci Rep, 2018, 8(1): 11720.
doi: 10.1038/s41598-018-29604-2 pmid: 30082828 |
[25] |
ALTEVOGT P, DOBERSTEIN K, FOGEL M. L1CAM in human cancer[J]. Int J Cancer, 2016, 138(7): 1565-1576.
doi: 10.1002/ijc.29658 pmid: 26111503 |
[26] |
LI Y, GALILEO D S. Soluble L1CAM promotes breast cancer cell adhesion and migration in vitro, but not invasion[J]. Cancer Cell Int, 2010, 10: 34.
doi: 10.1186/1475-2867-10-34 |
[1] | ZHANG Jingchen, LI Xin, LI Jiangtao, LI Haiping, CHEN Yanli, NIU Bing, QI Chuanchuan, YE Beibei. LINC02163 targeting miR-338-3p affects proliferation, invasion and migration of breast cancer cells [J]. China Oncology, 2022, 32(9): 818-826. |
[2] | Committee of Breast Cancer Society, Chinese Anti-Cancer Association, Breast Surgeons Committee of Surgeons Branch, Chinese Medical Doctor Association, Committee of Breast Cancer Society, Shanghai Anti-Cancer Association. Expert consensus on oncoplastic surgery of breast tumor and breast reconstruction (2022 edition) [J]. China Oncology, 2022, 32(9): 836-924. |
[3] | XIAO Yuling, ZHU Xiuzhi, JIANG Yizhou, SHAO Zhimin. New research advances and future prospect in precision treatment of triple-negative breast cancer [J]. China Oncology, 2022, 32(8): 669-679. |
[4] | QIU Pengfei, WANG Yongsheng. Precise regional management of breast cancer in the sentinel lymph node era: evolution and prospect [J]. China Oncology, 2022, 32(8): 680-687. |
[5] | ZHANG Yu, LIU Qiang. Advances of liquid biopsy in precision treatment of breast cancer [J]. China Oncology, 2022, 32(8): 688-697. |
[6] | ZHOU Wenbin, XIE Hui, DING Qiang, WANG Shui. New research progress of microwave ablation in the local precise treatment of early-stage breast cancer: the prospect of combined immunotherapy is promising [J]. China Oncology, 2022, 32(8): 698-704. |
[7] | LIU Yiming, FAN Lei, MO Miao, SHAO Zhimin, YU Keda. Factors-associated with short-term effect and long-term survival of ovarian function suppression in estrogen receptor positive breast cancer: a retrospective analysis [J]. China Oncology, 2022, 32(8): 705-711. |
[8] | XIAO Jialong, MO Miao, ZHOU Changming, WANG Zezhou, SHEN Jie, YUAN Jing, YU Keda, LIU Guangyu, WU Jiong, SHEN Zhenzhou, SHAO Zhimin, ZHENG Ying. The effect of the interaction between body mass index and age on the prognosis of breast cancer [J]. China Oncology, 2022, 32(8): 719-726. |
[9] | CHEN Anli, SHEN Haoyuan, YANG Shixiong, DENG Chunyan, HU Chaohua, LIU Hanzhong, WANG Shu, QIAN Fang. Predictive value of plasma long non-coding RNA H19 in neoadjuvant therapy for breast cancer [J]. China Oncology, 2022, 32(8): 727-735. |
[10] | LIU Qiang, FANG Yi, WANG Jing. Application progress of single-cell sequencing technology in breast cancer research [J]. China Oncology, 2022, 32(7): 635-642. |
[11] | QIAN Yao, LIU Feng. Research progress and prospects of neoadjuvant endocrine therapy for breast cancer [J]. China Oncology, 2022, 32(7): 643-649. |
[12] | JIA Xiaoqing, SUN Xiaoyin, JIANG Beiqi, MEI Zhangyi, FU Yun, ZHUANG Zhigang. Neddylation modification regulates lamin B1 expression in breast cancer [J]. China Oncology, 2022, 32(6): 535-541. |
[13] | LIU Jianlan, CHEN Daishi, HU Hong, ZHOU Dongxian, HU Jintao. Predictors of response to neoadjuvant treatment and changes to HER2 status in HER2-positive invasive breast cancer [J]. China Oncology, 2022, 32(5): 417-426. |
[14] | ZHANG Qian, FANG Xiaoyan, LIU Juan, LIU Jin, CHENG Leilei, SUN Jing. Study on the safety of simultaneous integrated boost and the importance of cardiac substructural dose assessment of hypofractionated radiotherapy after early left breast cancer breast-conserving surgery [J]. China Oncology, 2022, 32(5): 427-435. |
[15] | XU Bingqi, ZHANG Guoqiang. Advances in the diagnosis of pathological response by a second biopsy in breast cancer neoadjuvant therapy and their clinical significance [J]. China Oncology, 2022, 32(4): 335-342. |
Viewed | ||||||
Full text |
|
|||||
Abstract |
|
|||||
沪ICP备12009617
Powered by Beijing Magtech Co. Ltd